Professor and Head, Department of Oncology, Palacký University Medical School & Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
Anticancer Res. 2014 Mar;34(3):1115-25.
Despite the progress of tailored therapeutic strategies in patients with breast cancer, there is an unmet medical need for additional biomarkers that would guide therapy, including the administration of targeted agents. It has been demonstrated that the presence of tumor-infiltrating lymphocytes (TILs) is associated with prognosis in patients with early breast cancer. Moreover, TIL counts were shown to predict outcome of neoadjuvant chemotherapy. The neoadjuvant setting is increasingly used to assess the efficacy of new systemic therapies, and TILs are promising as a biomarker reflecting the immune response to tumor. Future studies should investigate on the integration of TILs as predictive biomarkers in patients treated with targeted- agents.
尽管针对乳腺癌患者的靶向治疗策略取得了进展，但仍需要额外的生物标志物来指导治疗，包括靶向药物的应用，这是未满足的医学需求。已有研究表明，肿瘤浸润淋巴细胞（TILs）的存在与早期乳腺癌患者的预后相关。此外，TIL 计数可预测新辅助化疗的疗效。新辅助治疗越来越多地用于评估新的系统治疗的疗效，而 TIL 作为反映肿瘤免疫反应的生物标志物具有很大的潜力。未来的研究应探讨将 TIL 作为预测生物标志物整合到接受靶向治疗的患者中。
